Heartflow, Inc. (NASDAQ:HTFL) Stock Has Consensus Price Target of $46.25

Heartflow, Inc. (NASDAQ:HTFL) has been given an average rating of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $46.25.

Several brokerages have commented on HTFL. JPMorgan Chase & Co. raised their price objective on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Piper Sandler reiterated an “overweight” rating and set a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. UBS Group initiated coverage on shares of Heartflow in a research report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 target price for the company. Wells Fargo & Company raised their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Finally, Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th.

Heartflow Stock Up 4.4%

Shares of NASDAQ HTFL opened at $49.74 on Wednesday. The stock has a market capitalization of $4.33 billion, a PE ratio of -27.18 and a beta of 2.73. The firm has a fifty day moving average of $45.02 and a 200-day moving average of $34.45. Heartflow has a 52-week low of $20.13 and a 52-week high of $54.32.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business had revenue of $64.08 million for the quarter. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Equities research analysts expect that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Activity at Heartflow

In other Heartflow news, insider Campbell Rogers sold 19,682 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $50.15, for a total value of $987,052.30. Following the transaction, the insider directly owned 79,956 shares of the company’s stock, valued at $4,009,793.40. This trade represents a 19.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84. Following the transaction, the chief financial officer owned 184,789 shares in the company, valued at approximately $9,250,537.34. This represents a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 265,205 shares of company stock worth $12,245,527. 7.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Heartflow

Several hedge funds and other institutional investors have recently bought and sold shares of HTFL. XXEC Inc. purchased a new stake in Heartflow during the 2nd quarter worth $2,524,764,000. Quantinno Capital Management LP purchased a new position in Heartflow in the 1st quarter valued at about $1,734,000. Sei Investments Co. boosted its position in Heartflow by 342.5% in the 1st quarter. Sei Investments Co. now owns 67,048 shares of the company’s stock valued at $1,631,000 after buying an additional 51,895 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Heartflow during the second quarter valued at about $19,096,000. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Heartflow during the second quarter worth about $910,000.

About Heartflow

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow.